Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study

Abstract excerpt

Background In locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/EGJC), deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) tumors exhibit high responsiveness to immunotherapy. The synergistic efficacy of neoadjuvant immunotherapy combined with chemotherapy in dMMR/MSI-H GC/EGJC remains uncertain. Methods The NICE trial is a multicentre, single-arm, exploratory phase 2...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Immunotherapy and Biomarkers
• Share to Esophageal Cancer Research and Treatment